How Can Toxicological Risks of Prodrugs Be Mitigated?
The toxicological risks associated with prodrugs can be mitigated through various strategies. These include careful metabolic profiling during drug development to understand the conversion pathways and potential toxic metabolites. Additionally, personalized medicine approaches, such as genetic testing for enzyme polymorphisms, can help predict individual responses and tailor dosing regimens accordingly. Furthermore, the use of advanced drug delivery systems can control the release and activation of prodrugs, reducing the risk of toxicity.
